Anacetrapib vs Placebo Anacetrapib: Number of Participants With Presumed Ischaemic Stroke
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.0319 | 0.0292 | 0.0348 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.0321 | 0.0294 | 0.035 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | -0.000265 | -0.00422 | 0.00369 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 0.992 | 0.876 | 1.12 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 0.991 | 0.873 | 1.13 | log | ClinicalTrials.gov | |
| Number needed to treat, for one fewer participant with the outcome on Anacetrapib than on Placebo Anacetrapib | 3,780 | from the risk difference interval | the interval includes no difference | ClinicalTrials.gov |
Groups 2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Anacetrapib | Anacetrapib: 100mg tablet daily | 485 | 15,225 | OG000 | ClinicalTrials.gov |
| Group 2 | Placebo Anacetrapib | Placebo anacetrapib: 1 tablet daily | 489 | 15,224 | OG001 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | SECONDARY | ClinicalTrials.gov |
| Title | Number of Participants With Presumed Ischaemic Stroke | ClinicalTrials.gov |
| Description | Presumed ischaemic stroke (i.e. not known to be haemorrhagic).~Secondary assessments involve intention-to-treat comparisons among all randomized participants of the effects of allocation to anacetrapib versus placebo during the scheduled treatment period. | ClinicalTrials.gov |
| Time frame | Randomized treatment phase during median follow-up period of 4.1years | ClinicalTrials.gov |
| Population | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification | ClinicalTrials.gov |
| NCT number | NCT01252953 | ClinicalTrials.gov |
| Phases | PHASE3 | ClinicalTrials.gov |
| Conditions | Atherosclerotic Cardiovascular Disease | ClinicalTrials.gov |
| Interventions | Anacetrapib, Placebo anacetrapib | ClinicalTrials.gov |
| Lead sponsor | University of Oxford | ClinicalTrials.gov |
| Results first posted | 2018-05-04 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT01252953?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.